Biotech · Public company · Cambridge, MA, US
Cullinan Therapeutics, Inc.
Ticker CGEM · SEC CIK 0001789972
Track this companyFree. Adds Cullinan Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials118 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline18
- CLN-049Phase 2 · Relapsed/Refractory Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- CLN-081Phase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Velinotamig specified dose on specified days.Phase 2 · Immune Thrombocytopenia (ITP)ClinicalTrials.gov · fetched Nov 12, 2026
- VK-2019Phase 2 · Nasopharyngeal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- AzacitidinePhase 1 · AML (Acute Myeloid Leukemia)ClinicalTrials.gov · fetched Nov 12, 2026
- Carboplatin AUC 6Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CLN-049Phase 1 · AML (Acute Myeloid Leukemia)ClinicalTrials.gov · fetched Nov 12, 2026
- CLN-617Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CLN-619Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CLN-619Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- CLN-978Phase 1 · SLEClinicalTrials.gov · fetched Nov 12, 2026
- CLN-978Phase 1 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- CLN-978Phase 1 · SjögrenClinicalTrials.gov · fetched Nov 12, 2026
- Datopotamab deruxtecan-dlnk (Dato-DXd)Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- pemetrexedPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 1 · AML (Acute Myeloid Leukemia)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHAPHASE1_PHASE2 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07738822 · fetched Nov 12, 2026
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML PatientsPHASE1 · NOT_YET_RECRUITING · started Oct 15, 2026ClinicalTrials.gov NCT07722767 · fetched Nov 12, 2026
- A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's DiseasePHASE1 · RECRUITING · started Oct 1, 2025ClinicalTrials.gov NCT07041099 · fetched Nov 12, 2026
- A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusPHASE1 · RECRUITING · started Jan 21, 2025ClinicalTrials.gov NCT06613360 · fetched Nov 12, 2026
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple MyelomaPHASE1 · ACTIVE_NOT_RECRUITING · started Sep 3, 2024ClinicalTrials.gov NCT06381141 · fetched Nov 12, 2026
- CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid TumorsPHASE1 · TERMINATED · started Dec 12, 2023ClinicalTrials.gov NCT06035744 · fetched Nov 12, 2026
- A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)PHASE1 · TERMINATED · started May 31, 2023ClinicalTrials.gov NCT05879744 · fetched Nov 12, 2026
- CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)PHASE1_PHASE2 · RECRUITING · started Nov 18, 2021ClinicalTrials.gov NCT05143996 · fetched Nov 12, 2026
- A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 29, 2021ClinicalTrials.gov NCT05117476 · fetched Nov 12, 2026
- A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 31, 2019ClinicalTrials.gov NCT04036682 · fetched Nov 12, 2026
- Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)PHASE1_PHASE2 · TERMINATED · started Apr 4, 2019ClinicalTrials.gov NCT03682055 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 10, 2026 · fetched Nov 12, 2026